Patients were categorized into three groups based on the mean HK2 levels and MT-RNR1 G709A status in HCC tumors, with Group I consisting of 17 patients with low HK2 and MT-RNR1 709G, Group II of 16 patients with low HK2 and MT-RNR1 709A or high HK2 and MT-RNR1 709G, and Group III of 9 patients with high HK2 and MT-RNR1 709A. This evidence concerns the gene MCAT and hepatocellular carcinoma.